Abstract
Objective: To investigate the prognostic value of serum Interleukin-15 (IL-15), Tumour Necrosis Factor-alpha (TNF-α), and Chitinase-3-like protein 1 (YKL-40) for predicting structural and clinical progression in knee osteoarthritis (OA). Methods: In a 36-month prospective cohort study, 320 participants with symptomatic knee OA (Kellgren-Lawrence [KL] grade 2-3) were assessed. Baseline serum biomarkers were quantified via high-sensitivity ELISA. Primary outcome was radiographic progression (increase in KL grade ≥1 or joint space narrowing [JSN] ≥0.5mm). Secondary outcomes included clinically important worsening in WOMAC pain (≥20%) and incidence of total knee arthroplasty (TKA). Results: Elevated baseline levels of IL-15, TNF-α, and YKL-40 were independent predictors of radiographic progression after multivariate adjustment (IL-15: OR 2.41, 95% CI 1.52–3.81; TNF-α: OR 2.08, 1.31–3.30; YKL-40: OR 2.85, 1.81–4.49). A composite High-Risk Inflammatory Phenotype (HRIP), defined as elevation in ≥2 biomarkers, demonstrated superior predictive capacity (OR 5.12, 3.02–8.68 for radiographic progression; HR 3.45, 1.95–6.10 for TKA). The addition of the HRIP to a clinical model significantly improved predictive discrimination (AUC increase from 0.68 to 0.79, p<0.001). Conclusion: Serum IL-15, TNF-α, and YKL-40 define a novel systemic inflammatory signature. The HRIP panel is a robust, independent prognostic tool that identifies patients at high risk for rapid OA deterioration, with significant potential for clinical trial stratification and personalised management.
Keywords
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.